Deep Tech Startups

OMTX develops machine learning tools and datasets for drug discovery, helping researchers globally identify new therapeutic mechanisms of action and accelerate the development of medicines.

1 investor

Omni3D manufactures large-format industrial 3D printers for production and tooling applications in aerospace, automotive, defense, and maintenance sectors. The company offers open-system printing solutions with industry-grade components and support services to businesses across Europe and globally.

1 investor

OmniBio develops biologically-inspired AI models for autonomous robots and machines used in manufacturing, agriculture, and construction. The technology enables robots to learn and adapt in dynamic environments without traditional sensors or connectivity.

1 investor

OmniBuds develops ear-worn biosensing earbuds that continuously monitor cardiovascular and physiological signals through AI-powered analysis. The platform serves researchers, clinicians, and health-conscious individuals seeking accessible, unobtrusive insight into their body's cardiovascular responses during daily life.

1 investor

Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.

1 investor

Omnispace develops satellite-based connectivity that delivers next-generation mobile service, spectrum flexibility, and compute directly to mobile devices on Earth. Following a merger with Lynk, the company launched Elveo Mobile to provide this direct-to-device connectivity.

1 investor

Order-made Medical Research Inc. (OMR) develops antibody drug discovery technologies, including its LIMAXYS platform for generating antibodies against multi-pass transmembrane targets, plus the INTAB and MUTAB platforms for internalizing and disease-specific mutation antibodies. The company aims to create new antibody-based therapies for hard-to-treat cancers, autoimmune diseases, and neurodegenerative disorders.

1 investor

ON.energy builds grid-safe, resilient energy infrastructure systems that integrate with existing power grids and support hospitals, data centers, and cities. The company focuses on making energy reliable, clean, abundant and affordable through AI-driven infrastructure solutions.

1 investor

Onava is a drug discovery company that combines AI-native protein engineering, autonomous orchestration of model training and experimental feedback, and high-throughput functional assays to develop next-generation therapeutics. Its platform uses a cross-program data flywheel where insights from each program inform future candidate optimization.

1 investor

OncoNano Medicine develops a proprietary nanotechnology platform for cancer therapeutics that targets the acidic tumor microenvironment to improve drug delivery to tumors. The company serves oncology patients and builds a pipeline of therapies designed for more precise cancer treatment.

1 investor

OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.

1 investor

Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.

1 investor

One Robot builds simulation environments with world models that enable robotics teams to train manipulation policies faster by learning physics and visuals from real robot experience, reducing reliance on physical hardware during development.

1 investor

OneVisage develops biometric authentication technology and OEM solutions aimed at preventing digital identity theft and phishing attacks. Its solutions are sold to large IT integrators, hardware manufacturers, cybersecurity vendors, and Identity & Access Management providers.

1 investor

Onlife develops spatial behavioral intelligence technology that combines online and offline data to deliver personalized, location-aware experiences across consumer and enterprise applications. The company uses spatial AI and behavioral models to inform real-time decisions for individuals, businesses, and municipalities.

1 investor

Ontario Centres of Innovation (OCI) is an ecosystem connector that supports the commercialization of academic intellectual property and facilitates industry-academic collaborations to drive economic growth in Ontario. The organization invests in early-stage companies, supports SMEs in adopting emerging technologies, and develops talent across sectors including advanced manufacturing, clean technology, and automotive innovation.

1 investor

First Contact builds a high-fidelity tactile sensing glove with 847 pressure-sensing taxels per hand running at 240 Hz, including coverage on the sides and tips of the fingers. The device ships with a Python SDK and optional motion-capture support, targeting robotics and tactile data collection applications.

1 investor

Open Bionics develops 3D-printed bionic hands called the Hero Arm, designed to be affordable, functional, and aesthetically appealing alternatives to traditional prostheses. The company serves individuals with upper limb differences and limb loss, operating in the medical devices and assistive technology space.

1 investor

OpenProtein.AI offers protein language models and AI infrastructure for protein engineering, covering de novo sequence design, variant effect prediction, in silico screening, and training specialized models on proprietary data. Accessible via a no-code GUI and APIs, it serves biology and computational research teams working in protein design and drug discovery.

1 investor

Open Stent Solution develops a percutaneous medical device for mitral and tricuspid valve replacement in cardiac patients ineligible for open-heart surgery. The company leverages ribbon-based valve technology to enable less invasive treatment with smaller delivery systems adaptable to various valve sizes.

1 investor

Open Culture builds an automated laboratory platform (Habitat) that autonomously runs cell-culture experiments — perfusing, imaging, and recording living samples — and an AI agent that plans and executes experiments from plain-language descriptions while organizing results into a queryable knowledge graph. It serves neuroscience and biology research labs, drawing on the founders' prior Braingeneers work in electrophysiology and AI.

1 investor

OpenCV is a computer vision library that provides GPU-accelerated functionality for image processing and parallel computations. It enables developers to run vision algorithms on NVIDIA CUDA-enabled graphics processors while maintaining consistency with its CPU-based implementation.

1 investor

Openfabric AI is building a decentralized platform for AI services, aimed at connecting AI agents and letting network participants contribute computing power for AI execution and training. It focuses on decentralization, usability, security, an in-built exchange medium for AI services, interoperability, and scalability.

1 investor

Opera is an agentic security operations platform designed for cyber-physical environments, providing security capabilities for physical and digital security integration.

1 investor